| for the three months ended
December 31, |
for the twelve months ended
December 31, |
|||||||
| In 000€ | 2021 |
2020 (*) |
2021 |
2020 (*) |
||||
| Net profit (loss) for the period | 4,762 |
(2,039) |
13,145 |
(7,192) |
||||
| Income taxes | 490 |
(531) |
591 |
(1,028) |
||||
| Financial expenses | 919 |
1,073 |
4,101 |
5,996 |
||||
| Financial income | (1,195) |
(477) |
(5,620) |
(2,453) |
||||
| Depreciation and amortization | 5,277 |
5,160 |
20,516 |
19,775 |
||||
| Share in loss of joint venture | - |
- |
- |
39 |
||||
| EBITDA | 10,253 |
3,185 |
32,733 |
15,136 |
||||
| Share-based compensation expense (1) | 44 |
286 |
(834) |
1,344 |
||||
| Revaluation of fair value due to business combinations (2) | 8 |
(770) |
8 |
(770) |
||||
| Impairments (3) | 177 |
4,606 |
177 |
4,606 |
||||
| Acquisition-related expenses of business combinations (4) | 8 |
63 |
413 |
63 |
||||
| Adjusted EBITDA | 10,490 |
7,371 |
32,497 |
20,378 |
||||
| (1) |
Share-based compensation expense represents the cost of equity-settled and share-based payments to employees. | ||||||||||
| (2) |
Represents a positive revaluation of our initial 50% interest in RS Print after our acquisition of the remaining interest in the joint-venture. | ||||||||||
| (3) |
Impairments represents in 2021 the impairment of capitalized expenditures related to the goodwill of metal company Aldema BV (177kEUR), | ||||||||||
| and in 2020 the impairment of capitalized expenditures related to our tracheal splint development program (2,090kEUR) | |||||||||||
| and related to the goodwill and intangible assets of Engimplan (2,516 kEUR). | |||||||||||
| (4) |
Acquisition-related expenses of business combinations represents expenses incurred in connection with the RS Print acquisition in 2020. | ||||||||||
| (*) |
The year 2020 has been restated to reflect the final accounting of the business combination with RS Print. | ||||||||||
| Impact on Net profit for the period is 79 k€ and impact on (Deferred) income taxes is (79) k€. | |||||||||||
